‍Oslo, Norway – 30 July 2026 – RESPINOR AS, a Norwegian MedTech company pioneering non-invasive diaphragm monitoring technology, today announced that it has submitted a De Novo Classification Request to the U.S. Food and Drug Administration (FDA), seeking marketing authorization for RESPINOR DXT.®

The submission marks a major milestone in RESPINOR’s mission to make diaphragm monitoring more accessible at the bedside for critically ill patients. RESPINOR DXT has previously received FDA Breakthrough Device Designation and is CE marked and commercially available in Europe.

Weaning from mechanical ventilation is a high-risk process that has traditionally relied on intermittent, operator-dependent assessments of diaphragm function. Diaphragm dysfunction is a well-documented complication in mechanically ventilated adult ICU patients and is associated with prolonged ventilation, weaning failure, longer ICU and hospital stays, and increased mortality.

Supported by clinical evidence

RESPINOR DXT has been evaluated in clinical studies involving nearly 400 patients.

An early feasibility study validated the technology against conventional ultrasound and identified a diaphragm-excursion threshold of 1.1 cm for predicting weaning outcome. The findings were published in Critical Care in 2024.¹

The threshold was subsequently evaluated in two blinded, prospective, multicenter studies conducted at eight hospitals in France and Norway. Patients with diaphragm excursion below 1.1 cm had an eightfold higher risk of reintubation and spent, on average, two additional days in the ICU and five additional days in the hospital compared with patients above the threshold.²

A Paradigm Shift in ICU Respiratory Care

RESPINOR DXT is an ultrasound-based technology designed to provide operator-independent, continuous, real-time insight into diaphragm function, helping clinicians identify patients with low diaphragm excursion who may be at increased risk of extubation failure and supporting more informed extubation and ventilation decisions, for optimal patient care.

“Submitting our De Novo request is a major milestone for RESPINOR and an important step toward making reliable diaphragm monitoring available to critical care teams in the United States,”

said Trude Tingvoll, CEO of RESPINOR.

“Our clinical program demonstrates the potential importance of identifying patients with low diaphragm excursion before extubation. I am incredibly proud of the team that brought us to this point and grateful to the clinicians and patients who contributed to our clinical studies. We look forward to working with the FDA throughout the review process.”

RESPINOR DXT has not received FDA marketing authorization and is not commercially available in the United States.

About RESPINOR

RESPINOR AS is a Norwegian MedTech company headquartered in Oslo, dedicated to transforming intensive care through non-invasive, continuous monitoring of the diaphragm, the primary muscle of respiration. The company has developed RESPINOR DXT®, a novel ultrasound-based platform technology designed to provide real-time insight into diaphragm movement in mechanically ventilated patients. RESPINOR DXT® is CE marked under the EU Medical Device Regulation and is intended to support clinical decision-making during the weaning process from mechanical ventilation. RESPINOR DXT has received FDA Breakthrough Device Designation. RESPINOR is a privately held company.

Contact information:

Trude Tingvoll, CEO

Email: t.tingvoll@respinor.com

Phone: +47 474 53 313

Reference

1. Demoule A, Fossé Q, Mercat A, et al. Operator-independent continuous ultrasound monitoring of diaphragm excursion predicts successful weaning from mechanical ventilation: a prospective observational study. Critical Care. 2024;28:245.
2. Demoule A, Mercat A, Hyldebrandt JA, et al. Continuous diaphragm monitoring during the spontaneous breathing trial identifies patients at increased risk of extubation failure. Am J Respir Crit Care Med. 2024 [conference abstract]; full manuscript in preparation.

‍